Head-To-Head Contrast: Evaxion A/S (EVAX) vs. The Competition

Evaxion A/S (NASDAQ:EVAX – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Evaxion A/S to related businesses based on the strength of its institutional ownership, analyst recommendations, earnings, valuation, risk, dividends and profitability.

Valuation and Earnings

This table compares Evaxion A/S and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Evaxion A/S $7.53 million -$7.71 million -2.30
Evaxion A/S Competitors $688.58 million $7.69 million -18.30

Evaxion A/S’s rivals have higher revenue and earnings than Evaxion A/S. Evaxion A/S is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

11.0% of Evaxion A/S shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 41.6% of Evaxion A/S shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Evaxion A/S and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evaxion A/S 1 0 4 0 2.60
Evaxion A/S Competitors 9941 15328 45742 1605 2.54

Evaxion A/S currently has a consensus price target of $11.25, suggesting a potential upside of 304.68%. As a group, “Biotechnology” companies have a potential upside of 133.42%. Given Evaxion A/S’s stronger consensus rating and higher probable upside, research analysts clearly believe Evaxion A/S is more favorable than its rivals.

Volatility & Risk

Evaxion A/S has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Evaxion A/S’s rivals have a beta of -1.84, indicating that their average share price is 284% less volatile than the S&P 500.

Profitability

This table compares Evaxion A/S and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Evaxion A/S N/A -61.43% -34.23%
Evaxion A/S Competitors -12,224.75% -204.85% -31.52%

Summary

Evaxion A/S beats its rivals on 8 of the 13 factors compared.

Evaxion A/S Company Profile

(Get Free Report)

Evaxion A/S is a Denmark-based biotechnology company that uses artificial intelligence to discover and develop immunotherapies and vaccines. Its research focuses on treatments for cancer and infectious diseases, with the goal of identifying targets that can prompt the immune system to recognize and attack disease. The company’s pipeline includes personalized cancer immunotherapy candidates, including EVX-01, as well as vaccine programs for cancer and infectious diseases. Evaxion uses proprietary AI platforms to analyze biological data and identify potential targets for these programs.

Receive News & Ratings for Evaxion A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion A/S and related companies with MarketBeat.com's FREE daily email newsletter.